New-Onset Autoimmune Diabetes Mellitus Presenting As Diabetic Ketoacidosis in Association With Pembrolizumab Therapy and Long Term Follow-Up: Case Report

Pembrolizumab, an immune checkpoint inhibitor (ICI) that acts against receptor programmed cell death-1 (PD-1), is currently being used in the treatment of a variety of cancers. As PD-1 is also present on other non-malignant tissues, this results in side effects involving a multitude of organ systems...

Descripción completa

Detalles Bibliográficos
Autores principales: Pachpande, Vrushali, Mullangi, Sanjana, Lekkala, Manidhar Reddy, Patel, Arpan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132754/
https://www.ncbi.nlm.nih.gov/pubmed/35651416
http://dx.doi.org/10.7759/cureus.24479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132754/
https://www.ncbi.nlm.nih.gov/pubmed/35651416
http://dx.doi.org/10.7759/cureus.24479

Ejemplares similares